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Abstract Ubiquitin-immunoreactive neuronal inclusions
composed of TAR DNA binding protein of 43 kDa (TDP-
43) are a major pathological feature of frontotemporal lobar
degeneration (FTLD-TDP). In vivo studies with TDP-43
knockout mice have suggested that TDP-43 plays a critical,
although undeﬁned role in development. In the current
report, we generated transgenic mice that conditionally
express wild-type human TDP-43 (hTDP-43) in the fore-
brain and established a paradigm to examine the sensitivity
of neurons to TDP-43 overexpression at different develop-
mental stages. Continuous TDP-43 expression during early
neuronal development produced a complex phenotype,
including aggregation of phospho-TDP-43, increased
ubiquitin immunoreactivity, mitochondrial abnormalities,
neurodegeneration and early lethality. In contrast, later
induction of hTDP-43 in the forebrain of weaned mice pre-
vented early death and mitochondrial abnormalities while
yielding salient features of FTLD-TDP, including progres-
sive neurodegeneration and ubiquitinated, phospho-TDP-43
neuronal cytoplasmic inclusions. These results suggest that
neurons in the developing forebrain are extremely sensitive
to TDP-43 overexpression and that timing of TDP-43 over-
expression in transgenic mice must be considered when
distinguishing normal roles of TDP-43, particularly as they
relate to development, from its pathogenic role in FTLD-
TDP and other TDP-43 proteinopathies. Finally, our adult
induction of hTDP-43 strategy provides a mouse model that
develops critical pathological features that are directly
relevant for human TDP-43 proteinopathies.
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Introduction
TAR DNA binding protein (TDP-43), encoded by the
TARDBP gene on human chromosome 1, is a major patho-
logicalcomponentoftheneuronalinclusionsassociatedwith
amyotrophic lateral sclerosis (ALS) and frontotemporal
lobar degeneration (FTLD-TDP) [28]. The neuropathology
of these conditions is characterized by ubiquitin- and
TDP-43-positive neuronal and glial cytoplasmic inclusions,
neuronal intranuclear inclusions, and dystrophic neurites.
The majority of ALS cases have TDP-43 pathology, except
for cases caused by either SOD1 or FUS mutations [28].
TARDBP mutations have been identiﬁed in ALS, but they
onlyaccountfor4 %offamilialand 1.5 %ofsporadic cases
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DOI 10.1007/s00401-012-0979-3[25]. FTLD-TDP is the most common FTLD subtype
accountingfornearly50 %ofallcases[8,12],butonlythree
FTLD patients have been identiﬁed with TARDBP sequence
variants [5, 6, 20]. Recently, expansion repeats in the
C9ORF72 gene have been identiﬁed as the most common
genetic abnormality in familial FTLD-TDP and ALS [13,
30].TDP-43pathologyintheabsenceofTARDBPmutations
is also found in hippocampal sclerosis of the elderly, as well
asasubsetofpatientswithAlzheimer’sdisease,Parkinson’s
diseaseorotherneurodegenerativedisorders[2,3,15,17,18,
29, 37], suggesting a pervasive involvement of TDP-43 in
neurodegeneration. Therefore, pathology with wild-type
TDP-43 is associated with a range of both primary and sec-
ondary TDP-43 proteinopathies.
TDP-43 plays a role in transcription and splicing regu-
lation, with the number of target genes constantly growing.
Other functional roles that are not well characterized
include microRNA processing, RNA transport, cell divi-
sion, and apoptosis [7]. It is currently unclear if TDP-43
promotes neurodegeneration through a loss of one or more
of these functions or through a toxic gain of function or
both. Loss of TDP-43 in mice is lethal at any age [9, 21, 32,
42], supporting loss of function as a potential neurode-
generative mechanism. Conversely, the phenotypes of
several transgenic TDP-43 mouse models have been
strikingly consistent, including weight loss, gait abnor-
malities, abnormal hind limb escape reﬂex, and early
lethality [35, 40, 41, 43]. These ﬁndings suggest that even
low levels of human TDP-43 (hTDP-43) overexpression
are pathogenic, regardless of wild type or mutant origin. A
number of studies from our lab and others have now shown
that murine TDP-43 is reduced in response to the overex-
pression of exogenous TDP-43; one study reported on a
conditional TDP-43 model similar to that utilized for our
current study [19]. None of these studies have examined
the impact of TDP-43 overexpression on neurons at dif-
ferent stages of development.
Given evidence that TDP-43 may be critically involved
in both development and neurodegeneration, we designed a
transgenic mouse model, termed iTDP-43WT that condi-
tionally expresses TDP-43 under the control of the
tetracycline conditional system of gene regulation [16].
These transgenic mice allowed us to determine if overex-
pression of hTDP-43 in neurons at different stages of
maturation alters the impact of TDP-43. Here, we show
that moderate hTDP-43 overexpression within the devel-
oping forebrain results in a complex phenotype, including
early lethality, early and extensive neuronal loss with
apoptosis, perikaryal clusters of abnormal mitochondria
and cytoplasmic inclusions of phosphorylated TDP-43 as
well as increased ubiquitin immunoreactivity and gliosis.
We also show that speciﬁc induction of hTDP-43 later in
forebrain maturation prevents early lethality, severe early
onset neurodegeneration, and mitochondrial abnormalities,
yet produces salient features of FTLD-TDP, including
progressive neuronal loss, reactive gliosis, and TDP-43
inclusions that co-localize with ubiquitin. These mice now
provide a model in which developmental effects of TDP-43
overexpression can be distinguished from degenerative
effects of TDP-43 in the mature nervous system.
Materials and methods
Ethics statement
All mice were utilized with approval and in accordance
with the Mayo Clinic Institutional Animal Care and Use
Committee and the University of Florida Institutional
Animal Care and Use Committee.
Transgenic mice
iTDP-43WT mice were generated similarly to a previously
described protocol [31]. Full length, untagged, human
TDP-43 cDNA, ampliﬁed using a TDP-43-myc plasmid as
a template [44], was inserted into the inducible expression
vector pUHD 10-3 (Hermann Bujard, ZMBH) containing
ﬁve tetracycline operator sequences. The construct was
conﬁrmed by restriction enzyme digest and direct
sequencing. The transgenic fragment was obtained by
BsrBI digestion, gel puriﬁed followed by b–agarase
digestion (NEB), ﬁltration and concentration. The modiﬁed
TDP-43 transgene was injected into the pronuclei of donor
FVB/NCr embryos (Charles River). These responder mice
were bred with 129S6 mice (Taconic) with the tetracycline
transactivator (tTA) transgene downstream of calcium-
calmodulin kinase II alpha (CaMKIIa) promoter elements
[27] to produce the iTDP-43WT transgenic mice with
forebrain hTDP-43 expression. For TDP-43 transgene
suppression studies during development, doxycycline water
(1.5 g/l doxycycline and 4 % sucrose) was placed in
breeding cages for 2 days in addition to doxycycline diet
(Harlan; 200 mg/kg), which remained in the breeding cage
until pups were weaned at 21 days. Doxycycline, a tetra-
cycline derivative, binds tTA and prevents transgene
expression. At 21 days, weanlings were placed in cages
with regular chow to allow hTDP-43 transgene expression
to commence.
Immunohistochemistry
After euthanasia via cervical dislocation, brains were har-
vested and divided along the midline. The right hemisphere
was ﬂash-frozen on dry ice, while the left hemisphere was
drop ﬁxed in 10 % neutral buffered formalin for
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123histological analyses. Brains were embedded in parafﬁn
and cut into 5-lm sagittal sections. Tissues were immu-
nostained with monoclonal antibodies to TDP-43, pS403/
404-phosphorylated TDP-43, ubiquitin, ionized calcium-
binding adaptor molecule 1 (Iba1), glial ﬁbrillary acidic
protein (GFAP), and cytochrome C oxidase subunit IV
(COX-IV), using the DAKO Autostainer (DAKO Auto
Machine Corporation, Carpinteria, CA) with DAKO
Envision? HRP System. For cleaved caspase 3 and neu-
ronal nuclear antigen (NeuN) double labeling, the DAKO
Envision G2 Double Stain System was used. The peroxi-
dase labeling of cleaved caspase 3 was visualized with
diaminobenzidine (DAB), and the alkaline phosphatase
labeling of NeuN was detected with Vector Blue alkaline
Phosphatase Substrate Kit III (Vector Laboratories,
Burlingame, CA). See Supplementary Table 1 for a com-
plete list of primary antibodies used. Hematoxylin and eosin
(H&E) staining was performed by standard procedures.
Protein isolation and Western blotting
Brains were weighed and homogenized in lysis buffer
(50 mM Tris base, 274 mM NaCl, 5 mM KCl pH 8.0, 1 %
Triton X-100, 2 % SDS, and protease and phosphatase
inhibitors) at 1 ml/100 mg. Samples were sonicated and
centrifuged at 16,200g for 20 min at 20 C. Supernatant
protein concentration was determined by BCA assay
(Pierce). Approximately, 50 lg protein was loaded onto
10 % Tris–glycine polyacrylamide gel (Novex). After
electrophoresis, gels were transferred to a nitrocellulose
membrane for 2 h at 200 mA constant current. Membranes
were blocked with 5 % milk in Tris-buffered saline and
0.1 % Triton X-100 (TBS-T; Sigma-Aldrich) for 1 h and
probed overnight at 4 C with one of the following primary
antibodies in 5 % TBS-T: mouse monoclonal TDP-43
antibody recognizing human TDP-43, rabbit polyclonal
TDP-43 antibody recognizing total TDP-43, and mouse
monoclonal glyceraldehyde-3-phosphate dehydrogenase
antibody (GAPDH). See Supplementary Table 1 for a
complete list of primary antibodies used. The membrane
was washed 5 times for 5 min in TBS-T and then incubated
in the appropriate secondary antibody for 1 h. The mem-
brane was again washed 5 times for 5 min in TBS-T. ECL
reagent was added for 2 min, and the membrane was
exposed to X-ray ﬁlm. For reprobing, the membrane was
stripped with 70 mM SDS in Tris HCl (pH 6.8) with 0.7 %
BME for 15 min at 55 C before processing as described
above.
Quantitative PCR
Total RNA was isolated from dissected hippocampus and
cortex using TRIzol reagent (Invitrogen) and Pure Link
RNA Mini Kit (Invitrogen), and 2 lg were used to syn-
thesize cDNA using the High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems). All samples were
run in triplicate on the BioRad CFX384 Real-Time PCR
Detection System. A dilution series was used to construct a
standard curve for each primer pair from which normali-
zation and subsequent fold change calculations were
performed. Primer sequences for qPCR were mouse
Tardbp F (AAAGGTGTTTGTTGGACGTTGTACAG),
mouse Tardbp R (AAAGCTCTGAATGGTTTGGGAATG),
Gapdh F (CATGGCCTTCCGTGTTCCTA) and Gapdh R
(CCTGCTTCACCACCTTCTTGAT). Single PCR prod-
ucts were veriﬁed by melt curve analysis.
TUNEL staining
The ApopTag Peroxidase In Situ Apoptosis Detection Kit
(Chemicon) was used to detect DNA fragmentation by
labeling the free 30-OH termini. Staining was performed
according to the manufacturer recommendations. TUNEL-
positive cells were visualized by the chromogen 30-30
diaminobenzidine (DAB) in sections that were counter-
stained with methyl green.
Immunoﬂuorescence staining
Parafﬁn sections of brain tissue were deparafﬁnized and
rehydrated in a graded series of alcohols. Tissue was
blocked in DAKO Protein Block for 1 h then incubated
with primary antibodies overnight at 4 C. See Supple-
mentary Table 1 for a complete list of primary antibodies
used. After washing, tissue was incubated in Alexa Fluor
488 and Alexa Fluor 568 secondary antibodies (1:500,
Invitrogen) for 1 h at room temperature. Vectashield with
DAPI (Vector Laboratories) was used to stain nuclei.
Images were captured using an Axio Imager.Z1 micro-
scope (Zeiss).
Quantiﬁcation of neurons, TDP-43 inclusions,
and caspase 3 immunoreactivity
Three samples per group were chosen and tissue sections
approximately 2.0–2.1 mm from the midline were used to
quantify the total number of neurons (labeled by NeuN)
and the number of neurons containing phospho-TDP-43
and ubiquitin inclusions in addition to neurons with cas-
pase 3 immunoreactivity. Immunoﬂuorescent staining was
performed as described above. Images were captured from
different cortical regions (primary motor cortex, secondary
motor cortex, and primary sensory cortex) per sample after
scanning slides at 409 with ScanScope (Aperio). Images
were analyzed with ImageScope software (Aperio) for
quantiﬁcation.
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123Results
Continuous hTDP-43 overexpression yields complex
pathological proﬁles
To generate iTDP-43WT mice, wild-type human TDP-43
(hTDP-43) cDNA was placed behind a minimal CMV
promoter with tetracycline operator sequences that
effectively blocked human hTDP-43 expression in single
transgenic mice (TDP-43WT). By crossing these mice
with mice expressing the tetracycline transactivator
(tTA) under the CaMKIIa promoter [26], we created
bigenic iTDP-43WT mice that expressed hTDP-43 in the
cortex, hippocampus, olfactory bulb, and striatum, which
is the expected expression pattern for this CaMKIIa
promoter (Fig. 1a, Supplementary Fig. 1). We further
examined hTDP-43 expression in various organs and
found only low level expression in the cervical spinal
cord (Fig. 1b).
We screened 90 potential founders, identiﬁed 7 over-
expressing lines and focused our studies on two founder
lines, 5a and 17d, that expressed TDP-43 at the highest
levels in response to the introduction of the tTA transgene.
iTDP-43WT mice derived from founder lines 5a and 17d
expressed human TDP-43 protein at 3- and 2-fold,
respectively, over endogenous TDP-43 levels in NT brain
(Fig. 1c, d). Some variability in hTDP-43 expression was
observed in the 17d line (range from 1.6- to 2.4-fold;
Fig. 1d). iTDP-43WT mice from both founder lines showed
negligible expression of the transgene in the absence of the
tTA activator (Fig. 1c). We and others have previously
reported that TDP-43 levels appear to be tightly regulated
[4, 19, 33, 43], and we found similar results in the iTDP-
43WT mice at the RNA level. Compared to NT, mTDP-43
RNA was down-regulated in both the cortex (0.821 ±
0.036; P = 0.027) and hippocampus (0.575 ± 0.062;
P = 0.015) of iTDP-43WT mice (17d) in response to the
overexpression of hTDP-43 (Fig. 1e, f). Without a com-
mercially available antibody for mTDP-43, we were unable
to speciﬁcally assess down-regulation of mTDP-43 at the
protein level; however, Igaz and colleagues [19] previously
demonstrated that endogenous mouse TDP-43 protein is
down-regulated in a similar model system.
Only 30 % of iTDP-43WT mice from the 5a founder line
survived past 2 months (2M) of age, while 80 % of iTDP-
43WT mice from line 17d survived through the same time
point (Fig. 1g). iTDP-43WT mice from both founder lines
that failed to survive past 2M were phenotypically similar,
showing reduced spontaneous activity, weight, and
grooming prior to death (Supplementary Fig. 2). These
data demonstrate that survival is dose dependent with
respect to hTDP-43 expression.
Neuronal loss is a prominent feature of TDP-43 pro-
teinopathies such as FTLD-TDP and ALS. We examined
the brains of iTDP-43WT mice and found that they had
striking forebrain atrophy regardless of phenotype (Fig. 2);
however, the extent of atrophy and the relative age at which
atrophy occurred were dramatically different than observed
in human TDP-43 proteinopathies, with almost complete
obliteration of neuroanatomical structures, such as the
dentate fascia of the hippocampus. Brains from iTDP-43WT
mice exhibit ventricular dilation, cortical thinning, reduced
cortical thickness and severe hippocampal atrophy, which
contribute to a macroscopic decrease in brain size (Fig. 2a–
d). While these features were present in both transgenic
lines, brains from symptomatic mice from both lines were
roughly twofold smaller than age-matched non-transgenic
(NT) mice (Fig. 2e, f). Postnatal brain weights of iTDP-
43WT mice from the 5a line had brain weights similar to NT
littermates until postnatal day 12 (Fig. 2e), suggesting that
early cortical and hippocampal development is not overtly
affected by hTDP-43 expression. In contrast, a drastic
decrease in brain weight was observed in symptomatic 5a
mice at 24d, implying that neuronalloss rapidlyoccurs from
P12 through the third postnatal week when the developing
mouse brain expands its axonal and dendritic arborizations
[22, 24] and synaptic pruning is ongoing [23]. 17d mice that
survived beyond 2M also had signiﬁcantly lower brain
weights than NT counterparts at all ages examined; how-
ever, the observed brain atrophy was not progressive
(Fig. 2f). Variability in expression level within the 17d line
did not directly correlate with brain weight. We sought to
determine if overt neuronal loss in iTDP-43WT mice was
due to apoptosis. All weaned iTDP-43WT mice examined,
regardless of line or phenotype, had elevated TUNEL-
positive cells in cortex and hippocampus in comparison to
age-matched NT mice, with the greatest number of apop-
totic cells in symptomatic mice from both lines
(Supplementary Fig. 3a). We determined that the cells
undergoing apoptosis were neurons by double immuno-
staining for cleaved caspase 3 and the neuronal marker
NeuN (Supplementary Fig. 3b) as well as their anatomical
location in nerve cell layers of cortex and hippocampus.
Overall, these results suggest that even moderate levels of
wild-type hTDP-43 overexpression are extremely toxic to
developing cortical and hippocampal neurons, causing
severe and early neuronal loss through apoptosis.
Histological examination was performed on both foun-
der lines. We compared symptomatic 5a and 17d mice to
17d mice without an observable phenotype at 2M.
Approximately 11 % of cortical neurons in symptomatic
mice from the 5a line contained small (\1 lm) punctate
cytoplasmic inclusions when probed with phosphorylation-
speciﬁc TDP-43 antibodies that were absent in NT mice
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Fig. 1 Overexpression of hTDP-43 in the developing forebrain leads
to reduced survival and TDP-43 biochemical changes. a Immuno-
staining of a symptomatic 24-day-old 5a bigenic TDP-43/tTA iTDP-
43WT mice (iT) sagittal brain section shows an hTDP-43 expression
pattern that is anticipated with the CaMKIIa promoter, which
includes the cortex (CTX), hippocampus (HIP), olfactory bulb
(OB), and striatum (STR). b Western blot of tissue lysates from
6-month 17d iT and non-transgenic (NT) mice from brain (Br), spinal
cord (SC), thigh muscle (TM), heart (He), kidney (Ki), spleen (Sp),
and liver (Li) probed for hTDP-43 reveals expression in the brain with
lower levels in the spinal cord of iT mice. c Western blot of brain
lysates of NT mice, transgenic mice containing only the TDP-43
responder (T), and bigenic TDP-43/tTA mice (iT) from the 17d
(2-month old) and 5a (symptomatic, 24-day old) founder lines using
antibodies that either detects human TDP-43 (hTDP-43) or both
endogenous mouse TDP-43 and hTDP-43 (total TDP-43). GAPDH
was used as a loading control. iT mice from founder line 17d have
roughly 29 levels of TDP-43 expression when compared to NT
controls while iT mice from 5a have roughly 39 overexpression.
Minimal leakiness is shown in the TDP-43 only mice from founders
17d and 5a. d Densitometric analysis of the relative units of total
TDP-43 normalized by the relative units of the GAPDH loading
control shown in panel (c). e, f Quantitative real time PCR using
murine-speciﬁc TDP-43 primers demonstrate reduced expression of
endogenous TDP-43 in 2-month-old 17d iT cortex (e) and hippo-
campus (f) relative to NT littermates, (n = 3). g A survival curve of
the 5a and 17d founder lines shows that iT mice from line 5a (n = 16)
only has a 30 % survival after 2 months, while the iT mice from line
17d (n = 110) has 80 % survival after 2 months compared to NT
controls (n = 168). SEM shown in d. Statistical analysis was assessed
by Student’s t test in e, f.* P\0.05
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123(pS403/404, Fig. 3a, b; pS409/410, Fig. 3c, e). Most
inclusions from the 17d line were also cytoplasmic, but the
mice that survived to 2M had pS403/404-positive-TDP-43
accumulations in the nucleus, particularly associated with
nuclear bodies (Supplementary Fig. 4). In addition to TDP-
43 inclusions, iTDP-43WT mice of both founder lines,
regardless of phenotype, had a general increase in ubiquitin
immunoreactivity predominantly located in neuronal peri-
karya and in neuritic processes compared to NT mice
(Fig. 3d, f, g and Supplementary Fig. 4). In some cases,
ubiquitin accumulated in punctate inclusions (Fig. 3f,
inset). Although pS409/410-TDP-43 and increased ubiq-
uitin immunoreactivity were both frequent, the two
co-localized in only about 50 % of the structures (Fig. 3c–e).
iTDP-43WT mice from both founder lines showed extensive
reactive microgliosis (Iba-1, Fig. 3h–i and Supplementary
Fig. 4) and astrocytosis (GFAP, Fig. 3j, k, Supplementary
Fig. 4) compared to NT mice; symptomatic mice displayed
the most robust gliosis. We also identiﬁed eosinophilic
aggregates within cortical and hippocampal neuronal
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Fig. 2 hTDP-43 overexpression in the developing brain results in
early and severe neuronal loss. a, b Hematoxylin and eosin (H&E)
staining of sagittal sections from symptomatic 5a iT mice (a) shows
considerable ventricular enlargement, cortical thinning, and hippo-
campal atrophy when compared to NT, (b) age-matched mice at
24 days of age. c, d Higher magniﬁcation of the sagittal sections
highlights the signiﬁcant ablation of CA1 and dentate gyrus in iT
(c) compared to NT (d) mice. Note the apoptotic bodies (c, inset)
suggesting the onset of apoptotic death in the CA1 of iT mice.
e Whole brain weights of 5a iT and NT mice at P0, P5, P12, P18 and
24-day old demonstrate that developing iT brains increase in weight
normally until P12 but drastically decrease in weight by 24-day old.
f Whole brain weights of 17d iT mice have signiﬁcantly lower brain
weights than NT mice at all ages examined but are most severe in the
symptomatic iT mice approximately 1-M old (range 24–45 days). Of
note, the brain weights of 17d iT mice that survived past 2 months of
age did not progressively decrease with age. The bar represents
2,500 lmi na, b and 500 lmi nc, d. Statistical analysis was assessed
by Student’s t test in e, f. ***P\0.001, **P\0.01
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Fig. 3 Developing neurons
with hTDP-43 overexpression
yield complex pathological
proﬁles. a, b Phosphorylation of
TDP-43 (pTDP-43, amino acids
403/404) was prominent in the
cytoplasm of 24-day-old
symptomatic 5a iT
(a) compared to NT (b) mice.
Enlarged inset (box)
demonstrates small, cytoplasmic
phospho-TDP-43 aggregates.
pTDP-43 immunostaining was
also observed within the
nucleus, primarily surrounding
nuclear bodies in neurons.
c–e Fluorescent
immunostaining of the cortex of
24-day-old symptomatic 5a iT
for pTDP-43 (amino acids
409–410; c; green) and
ubiquitin (d; red) partially
co-localize (e; yellow). DAPI
(e; blue) represents nuclear
staining. f, g Cortical
immunohistochemical staining
for ubiquitin in 24-day-old
symptomatic 5a iT mice
(f) shows a substantial increase
in ubiquitination when
compared to NT (g) mice.
Enlarged inset (box)
demonstrates occasional
cytoplasmic ubiquitin
aggregates. h, i Microgliosis
(Iba1) is apparent in 24-day-old
symptomatic 5a iT mice
(h) when compared to NT
(i) mice. j, k Cortical
immunohistochemical staining
for astrocytosis (GFAP) in
24-day-old symptomatic 5a iT
mice (j) shows abundant
reactive astrocytes when
compared to NT (k) mice.
l–n Fluorescent immunostaining
of the cortex of 24-day-old
symptomatic 5a iT for the
mitochondrial marker, COX-IV
(l; green), and ubiquitin
(m; red) demonstrates a large
perinuclear COX-IV aggregate
in a neuron with increased
ubiquitination (n). DAPI
(n; blue) represents nuclear
staining. Similar results were
obtained in line 17d
summarized in Supplementary
Table 2. The bar represents
100 lmi na, b, f–k and 20 lm
in c–e, l–n
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123perikarya that were positive for the mitochondrial marker
COX-IV (Supplementary Fig. 5). While the eosinophilic
aggregates were similar to those previously described by
our group and others in constitutive transgenic TDP-43
mice, they were smaller and less frequent than those
observed in the brainstem and spinal cord of constitutive
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123wild-type TDP-43 transgenic mice (TDP-43PrP)[ 33, 43].
Ultrastructurally, the juxtanuclear aggregates in the iTDP-
43WT mice were composed of abnormal mitochondria
(Supplementary Fig. 5), similar to that observed in the
spinal cord and brainstem of TDP-43PrP mice. Co-locali-
zation experiments demonstrated neurons with
mitochondrial aggregates often had increased ubiquitin
immunoreactivity (Fig. 3l–n), but the mitochondrial
aggregates themselves were not ubiquitinated. The mito-
chondrial aggregates were only present in iTDP-43WT mice
at 2M of age or younger. Symptomatic mice from both
founder lines showed the highest frequency of mitochon-
drial aggregates (Supplementary Fig. 5). In summary, the
pathological proﬁles of iTDP-43WT mice with hTDP-43
overexpression during early development is complex and
exhibits only limited features observed in human TDP-43
proteinopathies.
Induction of hTDP-43 expression after weaning
prevents early lethality phenotype
Given that hTDP-43 has been proposed to play crucial
roles in development, we sought to determine what features
of the phenotype observed in iTDP-43WT mice may be due
to the impact of hTDP-43 overexpression in the developing
forebrain as opposed to the TDP-43 mediated proteinopa-
thy. We utilized the conditional nature of this model to
suppress hTDP-43 expression during early development
with the introduction of doxycycline into the diet
(Supplementary Fig. 1). We focused our suppression
studies on line 5a, as this line had the most severe phe-
notype. hTDP-43 expression was suppressed in iTDP-43WT
mice from line 5a from conception until the mice reached
weaning age (21d), when cortical neurons have normally
matured and display extensively developed dendritic arb-
orizations and synaptogenesis has peaked [22, 24]. At
weaning, doxycycline was removed from the diet of the
iTDP-43 mice to allow hTDP-43 expression; we term these
mice diTDP-43WT.
None of the diTDP-43WT mice (n = 16) showed
reduced spontaneous activity, weight loss, or poor
grooming, which were the phenotypes observed in 70 % of
5a iTDP-43WT mice with continuous hTDP-43 expression.
In addition, diTDP-43WT mice had no decrease in survival,
with the oldest animal without an observable phenotype at
12M. To directly compare pathology between diTDP-43WT
and symptomatic iTDP-43WT 5a mice, we aged a cohort of
diTDP-43WT mice for 24d after induction of the hTDP-43
at weaning (ﬁnal age 45d). We chose this duration of
expression because 70 % of 5a iTDP-43WT mice with
continuous expression of hTDP-43 are moribund and must
be euthanized by postnatal day 24; therefore, both groups
of mice expressed the transgene for approximately the
same length of time. We also aged additional cohorts of
diTDP-43WT mice following induction of hTDP-43
expression to 5.5M and 11M to determine how the impact
of TDP-43 overexpression in the mature forebrain advan-
ces with age (Fig. 4a).
Biochemical examination revealed no difference in full-
length hTDP-43 or total TDP-43 expression between iTDP-
43WT and diTDP-43WT mice at 45d and 11M (Fig. 4b). The
5.5M diTDP-43WT mice exhibited a 20 % decrease in
hTDP-43. The symptomatic iTDP-43WT mice had more
low molecular weight species of hTDP-43 at around 35 and
25 kDa, with the latter also observed at 11M in the diTDP-
43WT mice. As in the iTDP-43WT 17d mice, mTDP-43
RNA levels within the cortex of diTDP-43WT (5a) mice
were down-regulated in response to overexpression of
hTDP-43 (0.664 ± 0.023; P = 0.003; Fig. 4c). Hippo-
campal mTDP-43 RNA levels were difﬁcult to assess as
the extensive atrophy within this region prevented a clear
delineation from surrounding tissue.
hTDP-43 induction after weaning produces key
pathological features of FTLD-TDP
While neuronal loss is a salient feature of FTLD-TDP and
other TDP-43 proteinopathies, the marked atrophy of the
cortex and near complete ablation of the hippocampus that
we observed in young iTDP-43WT mice with continuous
expression of hTDP-43 is far more severe and rapid than
Fig. 4 hTDP-43 induction in adult neurons overcomes early lethality
and results in a progressive neurodegeneration (Line 5a). a 5a iTDP-
43WT mice (iT) which continually expressed hTDP-43 were compared
to 5a diTDP-43WT mice (diT) in which hTDP-43 was suppressed with
doxycycline until weaning. Duration at hTDP-43 expression is shown
with green arrows. Duration of hTDP-43 suppression is shown with
red arrows. Final age of mice at analysis is listed at the end of each
arrow. b Western blot of brain lysates from a 24-day-old iT mouse
and diT mice at 45 days, 5.5 months, 11 months, and NT controls
shows that hTDP-43 levels were similar between iT mice and 45d and
11 M diT mice in which hTDP-43 had been induced post-weaning.
There was approximately 20 % decrease in hTDP-43 in 5.5M diT
mice. Increased lower molecular weight hTDP-43 products were
observed in the 24-day-old 5a iT mice at *35 and *25 kD, the latter
was also observed in the diT 11M old mice. Total TDP-43 levels were
equivalent across iT and diT mice. GAPDH was used as a loading
control. c Quantitative real time PCR using murine-speciﬁc TDP-43
primers demonstrates reduced expression of endogenous TDP-43 in
45-day-old diT mice in the cortex relative to NT littermates (n = 3).
d Whole brain weight comparison shows 45-day-old diT mice to be
equivalent to NT mice and signiﬁcantly greater than iT mice.
However, diT brain weight decreases with age and is signiﬁcantly less
than NT mice by 5.5 months. e–j H&E staining of diT (e–g) and NT
(h–j) mice at 45 days (e, h), 5.5 months (f, i), and 11 months
(g, j) reveals progressive dentate gyrus ablation and hippocampal
formation atrophy in addition to cortical thinning at 11 months.
Statistical analysis was assessed by Student’s t test in c, d. The bar
represents 500 lm. ***P\0.001, **P\0.01, *P\0.05, ns no
signiﬁcance
b
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123observed in any known human TDP-43 proteinopathy. To
determine if the marked brain atrophy that we observed in
the iTDP-43WT mice was due to hTDP-43 overexpression
in the environment of the developing forebrain, we com-
pared brain weights between iTDP-43WT, diTDP-43WT,
and NT mice (Fig. 4d). Brain weights of diTDP-43WT at
45 days were equivalent to NT controls and signiﬁcantly
increased (P\0.0001) over iTDP-43WT mice that were
matched for duration of hTDP-43 expression. The results
suggest that the brain atrophy observed in young iTDP-
43WT mice is due to overexpression of hTDP-43 in the
developing forebrain. In contrast, induction of hTDP-43
expression within more mature weanling forebrains yields
a progressive loss of brain weight that worsens with aging
(Fig. 4d), reaching signiﬁcance at 5.5 months (P = 0.010)
and further declining by 11 months (P = 0.0003).
Although no overt neurodegeneration was observed in the
diTDP-43WT cortex at 45 days (Fig. 4e, Supplementary
Fig. 6a), apoptotic bodies were detected, predominantly in
the dentate gyrus (Fig. 4e, inset). The hippocampal for-
mation in the diTDP-43WT mice at 45d onward was
signiﬁcantly atrophied compared to NT controls (Fig. 4e–j,
Supplementary Fig. 6b). Hippocampal atrophy progressed
with age and became severe at 11M at which point it was
accompanied by signiﬁcant cortical atrophy (Supplemen-
tary Fig. 6). Striking ablation of the dentate gyrus in
diTDP-43WT mice became apparent by 5.5 months and
progressed by 11 months (Fig. 4e–j). The dentate gyrus
had a relatively high quantity of TUNEL-positive cells
(Supplementary Fig. 7), correlating with this region having
the most striking neuronal loss (Fig. 4e–j).
We evaluated the brains of diTDP-43WT mice for the
presence of ubiquitin- and TDP-43-positive inclusions
observed in human TDP-43 proteinopathies. In contrast to
that observed in the iTDP-43WT mice, large ([1 um)
pS409/410-TDP-43 inclusions were predominant and
co-localized with ubiquitin 94 % of the time in 45d diTDP-
43WT mice (Fig. 5a–c). Interestingly, multiple inclusions
were often found within the same neuronal cell process.
These were distinct, punctate inclusions akin to the TDP-43
cytoplasmic inclusions observed in FTLD-TDP. These
inclusions drastically decreased in the 5.5M and 11M
diTDP-43WT mice (Fig. 5d). Because inclusions decreased
with age while neuronal loss increased with age, we sought
to determine whether neurons containing inclusions were
more susceptible to neuronal loss. Co-localization studies
revealed that 92 % of pS409/410-TDP-43 inclusions were
co-labeled for cleaved caspase 3 (Fig. 5e–g, Supplemen-
tary Fig. 8) in 45d diT mice.
Further immunohistochemical analyses revealed that the
number of cells expressing hTDP-43 within the nucleus of
diTDP-43WT mice decreased with age (Supplementary
Fig. 9), likely reﬂecting the selective loss of those neurons.
Diffuse cytoplasmic hTDP-43 immunoreactivity increased
with age in diTDP-43WT mice (Supplementary Fig. 9).
diTDP-43WT mice showed a moderate increase in activated
microglia with age (Fig. 6a–f), while reactive astrocytes
dramatically increased at 11 months (Fig. 6g–l) when
compared to NT mice. In summary, the pathological proﬁle
of diTDP-43WT mice with hTDP-43 overexpression in the
mature forebrain shared similarities with that observed in
human TDP-43 proteinopathies.
Degenerating and clustered mitochondria observed in
iTDP-43WT mice and other TDP-43 mouse models [33, 43]
are not typical of FTLD-TDP; therefore, we sought to
determine if this uncharacteristic phenotype observed in
iTDP-43WT mice was also present in diTDP-43WT mice. We
were not able to ﬁnd eosinophilic aggregates by H&E in
diTDP-43WT mice. Moreover, abnormal immunoreactivity
for COX-IV observed in iTDP-43WT mice (Fig. 7a) was not
observed in the diTDP-43WT or NT mice at any age exam-
ined (Fig. 7b–h), even in neurons with increased ubiquitin
immunoreactivity (Fig. 7i–k). These results suggest that the
mitochondrial abnormality observed in iTDP-43WT mice
is, indeed, a consequence of hTDP-43 overexpression
before P21 during early neuronal development.
Because FTLD-TDP affects patients in mid to late life,
we sought to validate our observations from diTDP-43WT
mice with induction of hTDP-43 expression at weaning in
diTDP-43 mice with induction of hTDP-43 expression at
10M. diTDP-43 mice were raised from conception until
10M of age on doxycycline to suppress hTDP-43 expres-
sion. At 10M, doxycycline was removed from the diet and
the diTDP-43 mice were allowed to express hTDP-43 for
24 days. These mice are termed -10M ? 24d to denote
suppressed for 10 months then expressed for 24 days to
distinguish them from the previously described diTDP-43
mice at 45d. hTDP-43 expression was equivalent between
45d and -10M ? 24d diTDP-43WT mice, demonstrating
that expression of the hTDP-43 transgene were similar
regardless of length of doxycycline suppression (Supple-
mentary Fig. 10a). diTDP-43WT (-10M ? 24d) mice
formed large pS409/410-TDP-43 inclusions that co-local-
ized with ubiquitin in [90 % of the inclusion bearing
neurons, similar to that previously observed in the diTDP-
43 mice at 45d (Supplementary Fig. 10b–g). This result
demonstrates that pTDP-43 inclusions can readily form in
adult neurons and that the loss of inclusions observed in
5.5M and 11M diTDP-43WT mice following hTDP-43
induction at weaning does not reﬂect a general inability of
aged mice to form inclusions. Histological examination of
sagittal H&E sections revealed apoptotic bodies, mainly in
the dentate gyrus of the diTDP-43WT (-10M ? 24d) mice
(Supplementary Fig. 10h). Futhermore, moderate micro-
gliosis and astrocytosis were observed in diTDP-43WT
(-10M ? 24d) mice (Supplementary Fig. 10i, j). These
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123neuropathological features were elevated over that
observed in NT controls (Supplementary Fig. 10k–m). In
total, these preliminary results suggest that hTDP-43
induction in both young adult mice (45d) and older adult
mice (-10M ? 24d) demonstrate characteristic features of
FTLD-TDP.
Discussion
We have demonstrated that expression of hTDP-43 during
early development yields a severe and complex phenotype
(see Supplementary Table 2 for summary), including
aggregation of phosphorylated TDP-43 and gliosis; how-
ever, these features are also accompanied by early
lethality, extensive neuronal loss at an early age, TDP-43
inclusions that lack ubiquitin immunoreactivity and
mitochondrial abnormalities that are not typical of human
TDP-43 proteinopathies. A subset of the iTDP-43WT mice
does survive until at least 12M; however, it is not
uncommon for transgenic mice to show variable pene-
trance and survival rates, even when on an inbred
background [1, 10, 11, 14]. As with prior examples, it is
difﬁcult to pinpoint the cause of this bimodal survival;
however, it does not appear to be simply a matter of
transgene expression. One could conceive of unlimited
pathways through which this may occur including the
activity of ubiquitin-proteosomal system within each pup,
the ability of some pups to adjust mTDP-43 or other
unknown interacting factors quicker than others, individ-
ual pup distress during pregnancy and amount of care and
suckling that any one pup receives. It should be noted that
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123pups that escape the moribund phenotype still have sig-
niﬁcantly reduced brain weight (Fig. 2f).
hTDP-43 induction in the more mature forebrain of
weaned diTDP-43WT mice prevented early death, sponta-
neous movement deﬁcits, severe neurodegeneration and
mitochondrial abnormalities. While the loss of these fea-
tures is interesting, it is rather the gain of the salient
features of FTLD-TDP in diTDP-43WT mice over that
observed in iTDP-43WT mice that is the most compelling
ﬁnding of our study. diTDP-43WT mice showed slowly
progressing neurodegeneration, progressive gliosis and
punctate cytoplasmic TDP-43 inclusions with ubiquitin
immunoreactivity—each of these features closely mimics
that observed in human TDP-43 proteinopathies and
is not akin to that observed in iTDP-43WT mice (see
Supplementary Table 2 for summary). TDP-43 inclusions
were primarily in cortical and hippocampal neurons, a
distribution that correlates with the brain regions with
highest hTDP-43 expression.
We and others have previously shown that endogenous
mTDP-43 is down-regulated in response to hTDP-43
overexpression [4, 19, 33, 43]. We found that this was also
the case in the cortex and hippocampus of non-symptom-
atic 17d iT mice and in the cortex of diT 5a mice.
Importantly, heterozygous TDP-43 knockout mice express
TDP-43 at levels equivalent to control mice [21, 32, 42].
Recently, a report has demonstrated that TDP-43 controls
its own expression via a negative feedback loop in a human
cell line [4]. Our data support these results, suggesting that
neurons have a compensatory mechanism to control tightly
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Fig. 6 diTDP-43WT mice exhibit progressive gliosis. a–f Cortical
immunohistochemical staining for microgliosis (Iba1) in diT (line 5a)
(a–c) and NT (d–f) mice at 45 days (a, d), 5.5 months (b, e), and
11 months (c, f) exhibits a moderate increase in reactive microglia
with age in diT mice compared to NT mice. g–l Cortical
immunohistochemical staining for astrocytosis (GFAP) in diT (line
5a) (g–i) and NT (j–l) mice at 45 days (g, j), 5.5 months (h, k), and
11 months (i, l) reveals a striking increase in reactive astrocytes in
11-month diT mice. The bar represents 100 lm
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123TDP-43 levels. Moreover, this feedback mechanism
appears to be present at multiple stages of development.
These data implies that TDP-43 expression must remain
within a precise range for cellular homeostasis.
Early lethality observed in our iTDP-43WT mice and
other transgenic TDP-43 models continually expressing
hTDP-43 [35, 41, 43] indicates that hTDP-43 overexpres-
sion either results in an extremely rapid disease course in
mice or that TDP-43 plays a critical functional role during
development. The latter hypothesis was supported by one
of the ﬁrst published reports of TDP-43 mutations [34],
where chick embryos transfected with TDP-43 mutant
plasmids developed abnormal limb and tail buds and only
15 % reached the normal stage of maturation. In the
current report, the severe neuronal loss and brain atrophy in
iTDP-43WT mice continually expressing hTDP-43 occurs
in the developing forebrain and the severe brain atrophy
appears not to progress in the iTDP-43WT animals who live
beyond 2 months of age. To determine whether TDP-43
had an impact on early brain development, we exploited
the conditional nature of our model by inducing hTDP-43
expression later in development after weaning. We dem-
onstrated that all diTDP-43WT developmentally suppressed
mice survived without early lethality of continually
expressing iTDP-43WT mice. They did not have an overt
phenotype up to 12M, the oldest age examined. This result
is consistent with the recent report by Igaz and colleagues
[19], who described a conditional TDP-43 transgenic
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Fig. 7 Mitochondrial aggregates are absent in diTDP-43WT mice.
Cortical tissue of symptomatic 5a iT (a), diT (b–d), and NT
(e–h) mice at 24 days (a, e), 45 days (b, f), 5.5 months (c, g), and
11 months (d, h) demonstrates COX-IV immunopositive aggregates
within the iT mice that are absent from diT and NT mice at all ages.
i–k Fluorescent immunostaining of the cortex in 45-day-old diT mice
for the mitochondrial marker, COX-IV (i; green), and ubiquitin
(j; red) reveals mitochondria are not aggregated even when ubiquitin-
positive aggregates are present (k). DAPI (k; blue) represents nuclear
staining. The bar represents 100 lmi na–h and 20 lmi ni–k
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123mouse model under the control of a CaMKIIa promoter
similar to our current diTDP-43WT model. Igaz and col-
leagues generated a high expressing line (8- to 9-fold) with
a defective nuclear localization signal (hTDP-43DNLS) as
well as a low expressing (0.4- to 1.7-fold) wild type line
(hTDP-43-WT) where the transgene was suppressed until
postnatal day 28 with subsequent aging to 6M without
lethality. In contrast to the current report, Igaz and col-
leagues did not explore the differences between hTDP-43
induction in the developing brain when compared with
the mature brain; therefore, it is difﬁcult to determine if
continuous expression in their model would have produced
the severe phenotype and early lethality we observed in
continuously expressing mice. On the other hand, a con-
stitutive model over-expressing wild type TDP-43 at
twofold higher than endogenous levels under the CaMKIIa
promoter has been reported to have reduced survival
though not at the early time points that we have described
[36].
In the present study, iTDP-43WT mice developed fre-
quent neuronal perikaryal mitochondrial aggregates in the
cortex, particularly in layer V, and occasionally in the
hippocampus. Our group and others have previously gen-
erated transgenic models with continuous overexpression
of TDP-43 that develops mitochondrial aggregates [33, 43].
The neuronal cytoplasmic eosinophilic aggregates
observed in our iTDP-43WT model were much smaller than
those observed in the brainstem and spinal cord of our
previously reported constitutive TDP 43PrP mice [33, 43].
We did not observe eosinophilic aggregates and immuno-
histological (COX-IV) evidence of abnormal mitochondrial
clusters in the diTDP-43WT mice following post-weaning
induction of hTDP-43 in mature forebrain. Interestingly,
Igaz et al. also did not report the occurrence of mitochon-
drial clusters when they induced TDP-43 overexpression at
P28 in their inducible TDP-43 mice. Given our results, we
suggest that Igaz et al. did not report mitochondrial clus-
tering because they only expressed the TDP-43 transgene
in their mice from P28 onward. Our data suggest that the
mechanism through which TDP-43 regulates mitochondrial
biology occurs during early brain development, when the
brain appears to be unusually sensitive to hTDP-43 over-
expression. Our current iTDP-43WT lines combined with
the hTDP-43 post-weaning induction strategy will likely be
useful in elucidating how TDP-43 impacts mitochondrial
dynamics.
The early, severe neuronal loss and atrophy, with near
total ablation of the hippocampus was perhaps the most
striking phenotype that we observed in iTDP-43WT mice
but did not observe in diTDP-43WT mice. The severe
neuronal loss and atrophy in iTDP-43WT mice were
accompanied by comparable microgliosis and astrogliosis.
In contrast, diTDP-43WT mice at earlier ages had
equivalent brain weights as NT mice, but they had a pro-
gressive decrease in brain weight with increasing age—a
degenerative phenotype that is similar to the later onset,
progressive neuronal loss and gliosis that are features of
human TDP-43 proteinopathies. Igaz and colleagues pre-
viously reported that post-weaning (P28) induction of
hTDP-43DNLS (8- to 9-fold) or hTDP-43-WT (0.4- to
1.7-fold) resulted in progressive neuronal loss, which
suggests that TDP-43 dysregulation in the mature forebrain
results in progressive neurodegeneration regardless of
expression level [19]. Furthermore, both micro- and
astrogliosis increased with age in the diTDP-43WT mice.
These results strongly indicate that during early develop-
ment neuronal populations are highly sensitive to even
moderate (2- to 3-fold) levels of hTDP-43 overexpression.
The underlying mechanism through which this develop-
mental sensitivity to TDP-43 remains to be determined, but
we have identiﬁed the developmental window of selective
neuronal vulnerability and, therefore, we can postulate
which developmental milestones might be affected. The
timing of neuronal loss during the third postnatal week
suggests that neurogenesis and synaptogenesis are not
markedly affected by hTDP-43 overexpression. Instead, the
neuronal loss occurs when synaptic pruning is ongoing
[23] and dendritic and axonal arbors are increasing in
complexity [22, 24]. Consequently, activity-dependent
plasticity may be implicated, and interestingly TDP-43 has
been shown to act as an activity-responsive factor that
repressestranslationinthedendritesofhippocampalneurons
[39]. Thus, TDP-43 misregulation during this period could
have profound effects on RNA metabolism, which could be
highly toxic to neurons in the developing brain. In addition,
the role of overexpression of hTDP-43 on mitochondrial
pathology during early development may be associated with
compromise of energy dynamics in the immature neurons,
rendering them more prone to apoptosis. Certainly, the
availabilityoftheconditionalinvivomodeldescribedherein
will allow the ﬁeld to uncover the basis of the sensitivity of
developing neurons to TDP-43 misregulation.
While iTDP-43WT mice develop cytoplasmic inclusions
that have phosphorylated TDP-43, these inclusions only
occasionally had ubiquitin immunoreactivity. In contrast,
45-day-old diTDP-43WT mice developed distinct, punctate
TDP-43 inclusions in neuronal perikarya and cell pro-
cesses, which also had ubiquitin immunoreactivity. In this
respect, TDP-43 aggregates in diTDP-43WT mice are sim-
ilar in appearance to TDP-43 neuronal cytoplasmic
inclusions in FTLD-TDP. Interestingly, inclusions in
diTDP-43WT mice decrease in size and number with age,
suggesting that neurons containing these inclusions may be
preferentially lost. The hTDP-43DNLS model reported by
Igaz and colleagues also had decrease in inclusions with
time; however, the number of inclusions at peak was rare,
820 Acta Neuropathol (2012) 123:807–823
123ranging from \1t o\0.1 % depending on line [19]. In
contrast, the phospho-TDP-43 and ubiquitin immunoposi-
tive neuronal inclusions in the constitutive CaMKII-TDP-
43 Tg model reported by Tsai and colleagues were only
mentioned in mice 6-month old, so we cannot determine
when these inclusions became apparent or if they decreased
with age [36]. Our results strongly suggest that phospho-
TDP-43 aggregates are associated with neurotoxicity in
that they have co-localization with activated caspase 3.
Igaz and colleagues suggested that loss of murine TDP-43
within the nuclear compartment may render neurons in
inducible TDP-43 mice susceptible to neurodegeneration
[19]. Without a commercially available mTDP-43 anti-
body, we are unable to conﬁrm these ﬁndings; however,
RNA analysis suggests that a similar reduction of nuclear
mTDP-43 occurs within our iTDP-43WT mice. Importantly,
human and mouse TDP-43 are highly homologous [38]. It
would therefore seem surprising that a moderate (2- to
3-fold) level of human TDP-43 overexpression would be
incapable of compensating for the nuclear loss of mTDP-
43. Without the availability of an hTDP-43 knockin mouse,
it is difﬁcult to assess with certainty that the human TDP-
43 can compensate for murine TDP-43 in vivo.
In generating iTDP-43WT mice with forebrain expres-
sion, we sought to recapitulate features of FTLD-TDP and
other TDP-43 proteinopathies, but the conditional nature of
the model has also allowed us to determine the impact of
TDP-43 induction at different developmental periods on
the ensuing pathologic phenotype. Consequently, we report
for the ﬁrst time that the developing brain is more sensitive
to hTDP-43 overexpression than more mature brain,
despite having the same ability to autoregulate endogenous
mTDP-43 levels. In addition, the early, severe neuronal
loss and brain atrophy in iTDP-43WT mice probably has a
different pathogenesis from the progressive neurodegen-
eration observed in diTDP-43WT mice when expression of
transgene is delayed. Moreover, the present results suggest
that ubiquitinated, phospho-TDP-43 aggregates may
themselves be neurotoxic in mature neurons. Finally and
most critically, the timing of hTDP-43 overexpression
certainly affects the integrity of model phenotype as it
relates to FTLD-TDP. The availability of this new TDP-43
model system provides the ﬁeld with a more pathologically
similar transgenic mouse model for FTLD-TDP as well as
a system in which the role of TDP-43 in development
versus disease can now be distinguished.
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